Human pharmaceuticals in US surface waters: a human health risk assessment.

The detection of low levels of pharmaceuticals in rivers and streams, drinking water, and groundwater has raised questions as to whether these levels may affect human health. This report presents human health risk assessments for 26 active pharmaceutical ingredients (APIs) and/or their metabolites, representing 14 different drug classes, for which environmental monitoring data are available for the United States. Acceptable daily intakes (ADIs) are derived using the considerable data that are available for APIs. The resulting ADIs are designed to protect potentially exposed populations, including sensitive sub-populations. The ADIs are then used to estimate predicted no effect concentrations (PNECs) for two sources of potential human exposure: drinking water and fish ingestion. The PNECs are compared to measured environmental concentrations (MECs) from the published literature and to maximum predicted environmental concentrations (PECs) generated using the PhATE model. The PhATE model predictions are made under conservative assumptions of low river flow and no depletion (i.e., no metabolism, no removal during wastewater or drinking water treatment, and no instream depletion). Ratios of MECs to PNECs are typically very low and consistent with PEC to PNEC ratios. For all 26 compounds, these low ratios indicate that no appreciable human health risk exists from the presence of trace concentrations of these APIs in surface water and drinking water.

[1]  T. Ternes.  Occurrence of drugs in German sewage treatment plants and rivers 1 Dedicated to Professor Dr. Klaus , 1998 .

[2]  S. Weigel,et al.  Simultaneous solid-phase extraction of acidic, neutral and basic pharmaceuticals from aqueous samples at ambient (neutral) pH and their determination by gas chromatography-mass spectrometry. , 2004, Journal of chromatography. A.

[3]  P. Rao.  Who Food Additives Series , 1973 .

[4]  R Hirsch,et al.  Occurrence of antibiotics in the aquatic environment. , 1999, The Science of the total environment.

[5]  Ipcs,et al.  Assessing human health risks of chemicals; derivation of guidance values for health based exposure limits , 1994 .

[6]  T. Poiger,et al.  Occurrence and Environmental Behavior of the Chiral Pharmaceutical Drug Ibuprofen in Surface Waters and in Wastewater , 1999 .

[7]  A. Renwick.  Data-derived safety factors for the evaluation of food additives and environmental contaminants. , 1993, Food additives and contaminants.

[8]  Glen R. Boyd,et al.  Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada. , 2003, The Science of the total environment.

[9]  Ipcs,et al.  Toxicological Evaluation of Certain Veterinary Drug Residues in Food , 1989 .

[10]  C. Watts,et al.  Identification of Non-Volatile Organics in Water Using Field Desorption Mass Spectrometry and High Performance Liquid Chromatography , 1984 .

[11]  T. Ternes,et al.  Nachweis von Arzneimittelrückständen in Kläranlagen und Fliessgewässern , 1996 .

[12]  A. Aulinger,et al.  Pharmaceuticals in the river Elbe and its tributaries. , 2004, Chemosphere.

[13]  Robert S. Boethling,et al.  Improved method for estimating bioconcentration/bioaccumulation factor from octanol/water partition coefficient , 1999 .

[14]  R. Andreozzi,et al.  Carbamazepine in water: persistence in the environment, ozonation treatment and preliminary assessment on algal toxicity. , 2002, Water research.

[15]  Simon Webb,et al.  Indirect human exposure to pharmaceuticals via drinking water. , 2003, Toxicology letters.

[16]  Edward V. Sargent,et al.  A Human Health Risk Assessment of Pharmaceuticals in the Aquatic Environment , 2002 .

[17]  F. Christensen.  Pharmaceuticals in the environment--a human risk? , 1998, Regulatory toxicology and pharmacology : RTP.

[18]  Joint Fao,et al.  Book Review: Toxicological Evaluation of Certain Veterinary Drug Residues in Food , 2000 .

[19]  T. Heberer,et al.  Pharmaceuticals in the aquatic environment , 1997 .

[20]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[21]  K. Carlson,et al.  Evolution of antibiotic occurrence in a river through pristine, urban and agricultural landscapes. , 2003, Water research.

[22]  Thomas Ternes,et al.  Pharmaceuticals and Metabolites as Contaminants of the Aquatic Environment , 2001 .

[23]  N. S. Hewison.  Physicians' Desk Reference (PDR) , 1990 .

[24]  A. Avdeef,et al.  Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. , 1996, Journal of medicinal chemistry.

[25]  C. Berlin.  Effect of Nebulized Ipratropium on the Hospitalization Rates of Children with Asthma , 1999 .

[26]  John Struger,et al.  Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada , 2003, Environmental toxicology and chemistry.

[27]  H. Kay.  Environmental Health Criteria , 1980 .

[28]  T. Heberer,et al.  From municipal sewage to drinking water: fate and removal of pharmaceutical residues in the aquatic environment in urban areas. , 2002, Water science and technology : a journal of the International Association on Water Pollution Research.

[29]  J. Gaddum,et al.  The Pharmacological Basis of Therapeutics , 1966 .

[30]  T. Ternes,et al.  Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil. , 1999, The Science of the total environment.

[31]  D. Barceló,et al.  Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri. , 2001, Journal of chromatography. A.

[32]  S. Weigel,et al.  Determination of selected pharmaceuticals and caffeine in sewage and seawater from Tromsø/Norway with emphasis on ibuprofen and its metabolites. , 2004, Chemosphere.

[33]  K. Carlson,et al.  Routine monitoring of antibiotics in water and wastewater with a radioimmunoassay technique. , 2004, Water research.

[34]  Ettore Zuccato,et al.  Presence of therapeutic drugs in the environment , 2000, The Lancet.

[35]  K. Carlson,et al.  Solid-phase extraction-high-performance liquid chromatography-ion trap mass spectrometry for analysis of trace concentrations of macrolide antibiotics in natural and waste water matrices. , 2004, Journal of chromatography. A.

[36]  M. I C H A E,et al.  Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams, 1999-2000: A National Reconnaissance , 2002 .

[37]  M. Winkler,et al.  Selective degradation of ibuprofen and clofibric acid in two model river biofilm systems. , 2001, Water research.

[38]  M. Jekel,et al.  Detection and identification of sulphonamide drugs in municipal waste water by liquid chromatography coupled with electrospray ionisation tandem mass spectrometry. , 1999, Journal of chromatography. A.

[39]  R. Hannah,et al.  Environmental risk assessment of paroxetine. , 2004, Environmental science & technology.

[40]  Heinz P Singer,et al.  Occurrence and fate of carbamazepine, clofibric acid, diclofenac, ibuprofen, ketoprofen, and naproxen in surface waters. , 2003, Environmental science & technology.

[41]  M. Skopec,et al.  Urban contribution of pharmaceuticals and other organic wastewater contaminants to streams during differing flow conditions. , 2004, The Science of the total environment.

[42]  Guidance Document for the Use of Data in Development of Chemical-Specific Adjustment Factors ( CSAFs ) for Interspecies Differences and Human Variability in Dose / Concentration – Response Assessment , 2001 .

[43]  Peter Shanahan,et al.  Screening analysis of human pharmaceutical compounds in U.S. surface waters. , 2004, Environmental science & technology.

[44]  M L Dourson,et al.  Evolution of science-based uncertainty factors in noncancer risk assessment. , 1996, Regulatory toxicology and pharmacology : RTP.

[45]  T. Ternes,et al.  Nachweis von Betablockern und Bronchospasmolytika in der aquatischen Umwelt , 1996 .

[46]  J. Critchley,et al.  Factors determining the maintenance dose of warfarin in Chinese patients. , 1996, QJM : monthly journal of the Association of Physicians.

[47]  A. Bjørseth,et al.  Analysis of Organic Micropollutants in Water , 1982 .

[48]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[49]  Erin M. Snyder,et al.  Pharmaceuticals and personal care products in the waters of Lake Mead, Nevada , 2001 .

[50]  E. Thurman,et al.  Analysis of trace levels of sulfonamide and tetracycline antimicrobials in groundwater and surface water using solid-phase extraction and liquid chromatography/mass spectrometry. , 2001, Analytical chemistry.

[51]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[52]  Bruce D. Naumann,et al.  Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients , 1995 .

[53]  M. Krönke,et al.  Detection of pharmaceutical contaminations of river, pond, and tap water from Cologne (Germany) and surroundings. , 2002, International journal of hygiene and environmental health.

[54]  K. Takács-Novák,et al.  Lipophilicity of antibacterial fluoroquinolones , 1992 .

[55]  G. McEvoy,et al.  AHFS Drug Information , 1994 .

[56]  Christian G. Daughton,et al.  Pharmaceuticals and Care Products in the Environment: Scientific and Regulatory Issues , 2001 .

[57]  S. Weigel,et al.  Drugs and personal care products as ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in the North Sea. , 2002, The Science of the total environment.

[58]  A. Zaritsky,et al.  Effect of nebulized ipratropium on the hospitalization rates of children with asthma. , 1998, The New England journal of medicine.

[59]  A. Avdeef,et al.  pH-metric log P. II: Refinement of partition coefficients and ionization constants of multiprotic substances. , 1993, Journal of pharmaceutical sciences.

[60]  C. Lipinski,et al.  Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. , 1997, Journal of medicinal chemistry.

[61]  K. Thomas,et al.  Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry. , 2003, Journal of chromatography. A.

[62]  H. Brauch,et al.  Vorkommen von Arzneimittelwirkstoffen On oberflächenwässern , 1998 .

[63]  T. Heberer.  Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. , 2002, Toxicology letters.

[64]  H. Singer,et al.  Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng/l level in surface and waste water. , 2001, Journal of chromatography. A.

[65]  O. G. Fitzhugh,et al.  100-Fold margin of safety , 1954 .

[66]  Gun-Young Park,et al.  Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. , 2003, Environmental science & technology.

[67]  Edward V. Sargent,et al.  Establishing Data-Derived Adjustment Factors from Published Pharmaceutical Clinical Trial Data , 1999 .

[68]  G. Roberts,et al.  Observations on the thyroid gland in rats following the administration of sulfamethoxazole and trimethoprim. , 1973, Toxicology and applied pharmacology.

[69]  Frank Sacher,et al.  Removal of pharmaceuticals during drinking water treatment. , 2002, Environmental science & technology.

[70]  S. Eisenreich,et al.  Multi-component analysis of polar water pollutants using sequential solid-phase extraction followed by LC-ESI-MS. , 2003, Journal of environmental monitoring : JEM.

[71]  Ettore Zuccato,et al.  Strategic Survey of Therapeutic Drugs in the Rivers Po and Lambro in Northern Italy , 2003 .

[72]  R. Curini,et al.  Determination of Non-Steroidal Anti-Inflammatory Drugs in Surface Water and Wastewater by Liquid Chromatography-Tandem Mass Spectrometry , 2003, Chromatographia.

[73]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[74]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[75]  M. Reinhard,et al.  Occurrence and fate of pharmaceuticals and alkylphenol ethoxylate metabolites in an effluent‐dominated river and wetland , 2004, Environmental toxicology and chemistry.

[76]  S. Jørgensen,et al.  Occurrence, fate and effects of pharmaceutical substances in the environment--a review. , 1998, Chemosphere.

[77]  Pyrantel Embonate.  The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit , 1999 .

[78]  Brett J. Vanderford,et al.  Analysis of endocrine disruptors, pharmaceuticals, and personal care products in water using liquid chromatography/tandem mass spectrometry. , 2003, Analytical chemistry.